-To lay a technological foundation for developing exosome-based medicines and 
cosmetic products for dermatitis treatment 
-To prove the technological feasibility of ExoSCRT(TM) for the mass-production 
of the world's best exosomes with high efficacy

ExoCoBio Inc., one of global top 4 for stem cell exosome industry, announced 
that it received from Japanese Patent Office the patent which claims that stem 
cell-derived exosome is proved as effective ingredient for alleviating 
dermatitis (The registration number is 6970459). 

The patent is the result of the vigorous R&D efforts made to develop 
therapeutic medicines with higher efficacy and safety than currently known ones 
in relation to dermatitis with itching and inflammation. ExoCoBio found that 
the technology in the patent would solve the safety problem arising from stem 
cell or stem cell conditioned media by using ExoSCRT(TM) exosomes isolated from 
adipose stem cell conditioned media and thus prove the effectiveness of 
exosomes for prevention, improvement, alleviation or treatment of dermatitis. 
Furthermore, it is anticipated that the ExoSCRT(TM) exosomes will play a 
scientifically pivotal role as new medicine for dermatitis treatment.

Among therapeutic medicines currently marketed for the dermatitis are steroid, 
antihistamine, and immunosuppressive cyclosporine A etc. There are, however, 
growing concerns about serious side effects in relation with the use of them 
such as atrophodermia, vasodilation, loss of pigment, hypersensitivity after 
injection, tolerance and neutropenia etc. On the contrary, exosome-based 
medicines are expected to provide the fundamental treatment for inflammatory 
skin diseases without any serious side effect.

The key points of the patent cover following:

-ExoSCRT(TM) exosomes reduce the generation of inflammatory factors including 
inflammatory cytokine which are main causes of dermatitis;
-ExoSCRT(TM) exosomes can be developed as active principles of medicine or 
cosmetics to prevent, alleviate or treat the dermatitis by suppressing the 
activity of inflammatory immune cells;
-ExoSCRT(TM) exosomes promote the ceramide biosynthesis that is a key factor of 
skin barrier;
-It was scientifically proved that ExoSCRT(TM), technology developed by 
ExoCoBio for stem cell exosome production, plays a key role in producing high 
quality exosomes;

In connection with the patent, ExoCoBio published an article in the journal of 
Stem Cell Research & Therapy in 2018 according to which ExoSCRT(TM) exosomes 
alleviate atopic dermatitis with antibodies against surface markers (CD9, CD63, 
and CD81) (for the article, please visit the following: 
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-0939-5).

Additionally, as a supporting document, ExoCoBio published an article in the 
journal of Cells in 2020, according to which ExoSCRT(TM) exosomes promote de 
novo synthesis of ceramides in atopic dermatitis (for the article, visit the 
following: https://pubmed.ncbi.nlm.nih.gov/32164386/).

ExoCoBio expects that the patent will lay a technological foundation for 
regenerative aesthetics and medicines relating to prevention, alleviation or 
treatment of dermatitis. Furthermore, ExoCoBio anticipates its business 
opportunity in Japan for ExoSCRT(TM) exosomes based on the patent in the 
cosmetic and pharmaceutical fields.

SOURCE: ExoCoBio Inc.